Statement on Reproductive Justice
Medicines360 recognizes the importance of reproductive justice. We are aligned with the framework defined by SisterSong Women of Color Reproductive Justice Collective as “the human right to maintainpersonal bodily autonomy, have children, not have children, and parent the children we have in safe and sustainable communities.” The National Women’s Health Network (NWHN) and SisterSong issued […]
Medicines360 Appoints Rolf Jansen as Vice President of Drug Development and Manufacturing
Jansen to Lead Product Expansion Focused on Essential Medicines Facing Access Challenges SAN FRANCISCO – July 17, 2020 – Medicines360, a global nonprofit women’s health pharmaceutical organization, has appointed Rolf Jansen as the Vice President of Drug Development and Manufacturing. Mr. Jansen is a chemical engineer with more than thirty years of pharmaceutical experience developing […]
Statement on SCOTUS Ruling
On July 8, the Supreme Court of the United States (SCOTUS) ruled to uphold the Trump Administration’s regulations allowing employers and insurers to decline providing contraception coverage because of religious or moral objections. Implementation of these rules will immediately and significantly decrease contraceptive access for 70,500 to 126,400 women. When the rules were implemented in […]
Does a Low Cost for Clinics Mean More Underinsured Patients Are Able to Choose a Hormonal IUD? One Study in Utah Sought to Find Out
At the beginning of this year, an estimated 7.7 million women of reproductive age (15-44) in the United States were uninsured, with 2 million of these women living below the federal poverty level. As the ongoing novel coronavirus pandemic has led to historic numbers of unemployment claims, it is estimated that millions more have lost […]
Accessing Birth Control and Reproductive Health Services Amid COVID-19
Now more than ever, it is critical women have all the information and resources at their disposal to make informed decisions about their health. As the world grapples with the COVID-19 pandemic, women are facing more barriers than ever when it comes to accessing the birth control and reproductive health services they need. The healthcare […]
How America’s Nonprofit Pharma Industry Can Increase Access to Affordable Drugs
Access to affordable healthcare remains one of the largest issues in the United States. As we enter a new decade, we have the opportunity to create lasting change in drug pricing. Today, we join leaders across the nonprofit pharmaceutical industry to underscore the serious challenges facing Americans in accessing affordable drugs. Together, we hope to […]
Measuring Our Impact
When women can access affordable contraception, they can live their best and fullest lives. As part of our pioneering non-profit pharmaceutical business model, Medicines360 makes its product available at a price substantially below the 340B ceiling price set by statute to clinics participating in the 340B Drug Pricing Program. A key component of measuring our […]
Newly Published Data from Phase 3 Clinical Trial of LILETTA® (levonorgestrel-releasing intrauterine system) 52 mg Reinforces Efficacy for Longest-Approved Duration of Use for a Hormonal IUS
SAN FRANCISCO – December 17, 2019 – Medicines360, a global nonprofit women’s health pharmaceutical company, announced newly published data finding that LILETTA® (levonorgestrel-releasing intrauterine system) 52 mg is highly efficacious in preventing pregnancy for up to six years of use. The publication also reports data related to the bleeding profile over the same period of […]
FDA Approves Medicines360’s LILETTA® (levonorgestrel-releasing intrauterine system) 52 mg to Prevent Pregnancy for up to Six Years, the Longest Approved Duration of Use of Any Hormonal IUDs
SAN FRANCISCO and DUBLIN – Medicines360, a global nonprofit organization with a mission to expand women’s access to quality medicines, and Allergan plc (NYSE: AGN), a leading global pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) approved Medicines360’s Supplemental New Drug Application (sNDA) to extend the duration of use of LILETTA® (levonorgestrel-releasing […]
Pioneering the Nonprofit Pharmaceutical Industry
Medicines360 is a nonprofit women’s health pharmaceutical company in San Francisco. As a nonprofit, we answer to our mission: to remove cost as a barrier to health by developing and providing quality, affordable women’s health products. We were founded in 2009 and brought our first product to the U.S. market in 2015. We’re proud of […]
